bioAffinity Technologies announced a registered direct offering to raise approximately $4 million by selling common stock at $6.122 per share. This capital infusion is intended to fund working capital, support sales of its CyPath® Lung test, and for general corporate purposes, which could dilute existing shareholders.
bioAffinity Technologies is conducting a registered direct offering to raise approximately $4 million by selling common stock (or pre-funded warrants) at $6.122 per share. This capital raise is crucial for the company to fund its operations, particularly to support the growth of its CyPath® Lung product. While the capital infusion provides necessary liquidity and operational runway, the issuance of new shares will lead to dilution for existing shareholders, potentially putting downward pressure on the stock price in the short term. For traders, this presents a short-term risk due to dilution, but a long-term opportunity if the capital is effectively used to accelerate product sales and achieve profitability.